Consensus guidelines on anti-beta 2 glycoprotein I testing and reporting.
Consensus guidelines on anti-beta 2 glycoprotein I (anti-beta2GPI) testing have been developed to help minimise laboratory variation in the performance and reporting of assays for these antibodies. These guidelines include minimum and optional recommendations for the following aspects of anti-beta2GPI testing and reporting: (1) isotype of anti-beta2GPI tested; (2) specimen type; (3) controls and assay precision; (4) calibrators; (5) patient samples; (6) rheumatoid factors and IgM anti-beta2GPI testing; (7) reporting of results; (8) cutoff values; and (9) interpretative comments. Issues related to inter-kit/assay standardisation and the manufacturing process of commercial anti-beta2GPI kits/assays have not been addressed in the current guidelines.
Division of Immunology, Queensland Health Pathology Services, Royal Brisbane and Women's Hospital, Queensland, Australia. richard_wong@health.qld.gov.au
R C W
RC
Wong
E J
EJ
Favaloro
S
S
Adelstein
K
K
Baumgart
R
R
Bird
T A
TA
Brighton
M
M
Empson
D
D
Gillis
M J
MJ
Hendle
R
R
Laurent
D
D
Mallon
W
W
Pollock
S
S
Smith
R H
RH
Steele
R J
RJ
Wilson
D000888:Antibodies, Anti-Idiotypic / Q000097:blood* / Q000276:immunology; D016736:Antiphospholipid Syndrome / Q000097:blood / Q000175:diagnosis* / Q000276:immunology; D044362:Australasia; D002308:Cardiolipins / Q000276:immunology; D019411:Clinical Laboratory Techniques; D006801:Humans; D012680:Sensitivity and Specificity; D053482:beta 2-Glycoprotein I / Q000276:immunology*
D000888:Antibodies, Anti-Idiotypic; D002308:Cardiolipins; D053482:beta 2-Glycoprotein I